Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 8OTHER 5NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 31Rituximab 22Vincristine 19Doxorubicin 17Filgrastim 15Prednisone 14Peripheral Blood Stem Cell Transplantation 14Etoposide 13Cytarabine 12Magnetic Resonance Spectroscopy 10fludarabine phosphate 9Radiotherapy 9Bortezomib 9Biopsy 9Cyclosporine 8Specimen Handling 7Methotrexate 7Dexamethasone 7X-Rays 6Vorinostat 6Phantoms, Imaging 6Leucovorin 6Lenalidomide 6tanespimycin 5sargramostim 5fludarabine 5bryostatin 1 5aldesleukin 5Nuclear Medicine Department, Hospital 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Non-Hodgkin × acalabrutinib × Clear all
NCT04002947 2026-06-03

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
132 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡